Head-to-head · Cost-Efficiency Index
AgelessRx vs Alan Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
AgelessRx
Budget-first semaglutide shoppers who also want a longevity-medicine framing and occasional brand access.
Visit AgelessRxAlan Meds
Budget-first shoppers who want the lowest sema price plus an oral route nationwide.
Visit Alan MedsThe verdict
AgelessRx takes it, leading the Cost-Efficiency Index 85 to 84. The lowest published semaglutide cost among our partners, with some brand-name access — but an undisclosed tirzepatide price leaves a hole in the value model. Alan Meds still earns a B — Budget-first shoppers who want the lowest sema price plus an oral route nationwide.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs AgelessRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | AgelessRx | Alan Meds |
|---|---|---|
| Cost-Efficiency Index | 85/100 | 84/100 |
| Semaglutide / mo | $139/mo | $99/mo |
| Tirzepatide / mo | Not disclosed | $145/mo |
| Semaglutide / yr (modeled) | $1,668 | $1,188 |
| Tirzepatide / yr (modeled) | — | $1,740 |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #17 | #19 |
AgelessRx
85/100Where the value is
- Low disclosed semaglutide price at $139/mo
- Offers some brand-name access
- Established longevity brand
The tradeoffs
- Tirzepatide price not disclosed — you can't fully model total cost
- States-served not disclosed
Alan Meds
84/100Where the value is
- $99 semaglutide and $145 tirzepatide — among the cheapest disclosed in the ranking
- Nationwide all-50 access with an oral/sublingual option
- Both molecules published for straightforward cost modeling
The tradeoffs
- Not LegitScript-certified — oversight harder to verify
- Compounded only — no brand-name access
Regulatory note: the FDA issued a warning letter to Alan Health Technologies Inc. dba Alan in February 2026. We still list and link to Alan Meds; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.